Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign in or Register to read more
7488
Related Questions
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
What is your practice regarding giving G-CSF to patients with ALL during initial induction?
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
In pediatric patients with low-grade gliomas showing prolonged response or stable disease on tovorafenib, how would you adjust the duration of therapy?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
What cardiac surveillance would you do for an asymptomatic male patient with a remote history of mantle field radiation for Hodgkin's lymphoma?
How would you approach patients with primary cardiac sarcomas for adjuvant systemic treatment?
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?